Dan Goldstein's most recent trade in Pitney Bowes, Inc. was a trade of 7,892 Restricted Stock Units done . Disclosure was reported to the exchange on March 12, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Corp Sec. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2024 | 7,892 | 0 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Corp Sec. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2024 | 7,892 | 101,054 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Corp Sec. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.09 per share. | 12 Mar 2024 | 3,561 | 97,493 (0%) | 0% | 4.1 | 14,547 | Common Stock |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 1,260 | 89,817 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 1,260 | 112,895 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 07 Mar 2024 | 1,260 | 88,557 (0%) | 0% | 3.9 | 4,883 | Common Stock |
| Pitney Bowes Inc | Goldstein Daniel | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 125,313 | 364,754 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 7,891 | 91,031 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 7,891 | 14,134 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 14 Mar 2023 | 2,474 | 88,557 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,364 | 20,661 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,364 | 82,185 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.26 per share. | 21 Feb 2023 | 1,364 | 80,821 (0%) | 0% | 4.3 | 5,807 | Common Stock |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 114,155 | 238,595 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Purchase of securities on an exchange or from another person at price $ 3.32 per share. | 29 Jul 2022 | 3,013 | 80,821 (0%) | 0% | 3.3 | 10,000 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 62.60 per share. | 13 Jun 2022 | 42 | 4,447 (0%) | 0% | 62.6 | 2,629 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 62.69 per share. | 02 Jun 2022 | 249 | 4,489 (0%) | 0% | 62.7 | 15,610 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 59.10 per share. | 19 May 2022 | 134 | 4,738 (0%) | 0% | 59.1 | 7,919 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 2,029 | 2,029 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 868 | 4,872 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 56.10 per share. | 16 May 2022 | 50 | 4,004 (0%) | 0% | 56.1 | 2,805 | Common Stock |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2022 | 7,892 | 14,133 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2022 | 7,892 | 78,814 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 08 Mar 2022 | 2,474 | 76,340 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 101,833 | 225,886 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 3,352 | 69,360 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 3,352 | 18,673 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.91 per share. | 11 Feb 2022 | 3,352 | 66,008 (0%) | 0% | 4.9 | 16,458 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 59.87 per share. | 14 Jun 2021 | 39 | 4,054 (0%) | 0% | 59.9 | 2,335 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 55.09 per share. | 07 Jun 2021 | 81 | 4,093 (0%) | 0% | 55.1 | 4,462 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 1,753 | 4,174 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 2,690 | 2,690 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 994 | 2,463 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 55.19 per share. | 18 May 2021 | 42 | 2,421 (0%) | 0% | 55.2 | 2,318 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 55.98 per share. | 17 May 2021 | 42 | 1,469 (0%) | 0% | 56.0 | 2,351 | Common Stock |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 45,259 | 439,010 | - | - | Stock Option | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 23,675 | 124,943 | - | - | Restricted Stock Units | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 1,860 | 67,868 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.33 per share. | 16 Feb 2021 | 1,860 | 66,008 (0%) | 0% | 9.3 | 17,354 | Common Stock |
| Pitney Bowes Inc | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 1,860 | 20,165 | - | - | Restricted Stock Units | |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.21 per share. | 04 Feb 2021 | 1,457 | 3,206 (0%) | 0% | 34.2 | 49,844 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 1,457 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 135.84 per share. | 04 Feb 2021 | 1,457 | 1,749 (0%) | 0% | 135.8 | 197,919 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 500 | 1,503 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 135.72 per share. | 04 Feb 2021 | 500 | 1,749 (0%) | 0% | 135.7 | 67,860 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 98.03 per share. | 04 Feb 2021 | 500 | 2,249 (0%) | 0% | 98.0 | 49,013 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 476 | 952 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 135.88 per share. | 04 Feb 2021 | 476 | 1,749 (0%) | 0% | 135.9 | 64,679 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 93.52 per share. | 04 Feb 2021 | 476 | 2,225 (0%) | 0% | 93.5 | 44,516 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 136.26 per share. | 04 Feb 2021 | 238 | 1,511 (0%) | 0% | 136.3 | 32,430 | Common Stock |
| Haemonetics Corp | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 106.00 per share. | 26 Oct 2020 | 100 | 1,749 (0%) | 0% | 106 | 10,600 | Common Stock |